ArticleJournal of breast cancer2023
Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level.
Article in Journal of breast cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Effect of a whole food plant-based dietary intervention on cancer progression and inflammatory markers.The oncologist · 2025Trial
- Preoperative CA15-3 as a predictor of axillary lymph node metastasis and prognosis in women with breast cancer: a GRADE-assessed systematic review and meta-analysis.Breast cancer (Tokyo, Japan) · 2026Review
- Integrated Biomarker Assessment for Prognosis in Canine Mammary Carcinomas: Complementary Roles of Serum CA 15-3 and Immunohistochemistry Ki-67, and COX-2.Animals : an open access journal from MDPI · 2026Article
- Evaluating the Influence of Flaxseed Oil Against Docosahexaenoic Acid on Cancer Antigen CA15-3, Biochemical and Histopathological Parameters of DMBA-Induced Mammary Tumors Female Albino Wistar Rats.Food science & nutrition · 2026Article
- Diagnostic utility of postmortem serum tumor markers for identifying primary malignancies: A forensic evaluation of six markers.Forensic science, medicine, and pathology · 2026Article
- Biochemical landscape of breast cancer: integrating serum markers with clinical prognosis and staging.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Prognostic value of circulating HER2 extracellular domain in patients with HER2-positive metastatic breast carcinoma treated with TDM-1 (trastuzumab emtansine).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection.Scientific reports · 2026Article
- Diagnostic value of C-reactive protein-albumin-lymphocyte index in breast cancer cases.Frontiers in oncology · 2026Article
- Article
- A novel four-serum marker model for early detection and therapeutic monitoring of breast cancer.Scientific reports · 2025Article
- Synergistic Inhibition of Triple-Negative Breast Cancer by Acetylsalicylic Acid and Recombinant Human APE1/Ref-1 in a Mouse Xenograft Model.Biomedicines · 2025Article
- Prognostic value of CA15-3, CA125, CEA in breast cancer patients undergoing chemotherapy.Journal of medical biochemistry · 2025Article
- The Future of Tumor Markers: Advancing Early Malignancy Detection Through Omics Technologies, Continuous Monitoring, and Personalized Reference Intervals.Biomolecules · 2025Review
- Study of Glutathione S-Transferase, Its Isoenzyme (Pi), and Tumor Markers (CA15-3, HE4) in Breast Carcinoma Patients (Before and After Treatment).Journal of pharmacy & bioallied sciences · 2025Review
- Diagnostic Accuracy of Cancer Antigen 15-3 as a Seromarker Among Recurrent Breast Carcinoma in Bangladesh.Cureus · 2024Article
- Screen-Printed Electrodes as Low-Cost Sensors for Breast Cancer Biomarker Detection.Sensors (Basel, Switzerland) · 2024Review
- Potential Role ofClinical Medicine Insights. Oncology · 2024Article
- Method Comparison and Clinical Performance of Breast Cancer Tumor Markers on Novel Multiplex Immunoassay and Automatized LOCI Technology Platforms.Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeCancer antigen 15-3 (CA15-3) is a serum tumor marker for breast cancer (BC) extensively used in clinical practice. CA15-3 is non-invasive, easily available, and a cost-effective tumor marker for immediate diagnosis, monitoring and prediction of BC recurrence. We hypothesized that an elevation of CA15-3 may have prognostic impact in patients with early BC with normal serum CA15-3 level.
methodsThis was a retrospective cohort study, which included patients with BC who received curative surgery at a comprehensive single institution between 2000 and 2016. CA15-3 levels from 0 to 30 U/mL were considered normal, and patients who had CA15-3 > 30 U/mL, were excluded from the study.
resultsThe mean age of study participants (n = 11,452) was 49.3 years. The proportion of participants with elevated CA15-3 ≥ 1 standard deviation (SD) compared with the previous examination during follow-up was 23.3% (n = 2,666). During the follow-up (median follow-up 5.8 years), 790 patients experienced recurrence. The fully-adjusted hazard ratio (HR) for recurrence comparing participants with stable CA15-3 level to subjects with elevated CA15-3 level was 1.76 (95% confidence interval [CI], 1.52-2.03). In addition, if the CA15-3 was elevated ≥ 1 SD, the risk was much higher (HR, 6.87; 95% CI, 5.81-8.11) than in patients without elevated CA15-3 ≥ 1 SD. In sensitivity analysis, the recurrence risk was consistently higher in participants with elevated CA15-3 levels than in participants without elevated CA15-3 levels. The association between elevated CA15-3 levels and incidence of recurrence was observed in all subtypes and the association was stronger in patients with N+ than in patients with N0 stage (
conclusionThe results of the present study demonstrated that elevation of CA15-3 in patients with early BC and initial normal serum CA15-3 levels has a prognostic impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.